Process development of a SARS-CoV-2 nanoparticle vaccine

One of the outcomes from the global COVID-19 pandemic caused by SARS-CoV-2 has been an acceleration of development timelines to provide treatments in a timely manner. For example, it has recently been demonstrated that the development of monoclonal antibody therapeutics from vector construction to I...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinez-Cano, Diandra, Ravichandran, Rashmi, Le, Huong, Wong, H. Edward, Jagannathan, Bharat, Liu, Erik J., Bailey, William, Yang, Jane, Matthies, Kelli, Barkhordarian, Hedieh, Shah, Bhavana, Srinivasan, Nithya, Zhang, Jun, Hsu, Angel, Wypych, Jette, Stevens, Jennitte, Piedmonte, Deirdre Murphy, Miranda, Les P., Carter, Lauren, Murphy, Michael, King, Neil P., Soice, Neil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10019920/
https://www.ncbi.nlm.nih.gov/pubmed/37013198
http://dx.doi.org/10.1016/j.procbio.2023.03.014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10019920/
https://www.ncbi.nlm.nih.gov/pubmed/37013198
http://dx.doi.org/10.1016/j.procbio.2023.03.014

Ejemplares similares